Sustained release matrix systems for highly soluble drugs
AssigneePenwest Pharmaceuticals Co.
InventorsAnand R. Baichwal, Troy W. McCall, Lirong Liu, Steve Labudzinski
Life of this patent
Estimating the term…
Abstract
Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
Claims64
A sustained release oral solid dosage form comprising:
- an therapeutically effective amount of a medicament having a solubility of more than about 10 g/l;
- a pH modifying agent;
- a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
A sustained release oral solid dosage form comprising:
- an effective amount of a calcium channel blocker to provide a therapeutic effect, said calcium channel blocker having a solubility greater than 10 g/L;
- a pH modifying agent;
- a pharmaceutically acceptable surfactant
- a sustained release excipient comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing bimodal absorption profile of said calcium channel blocker and providing a sustained release of said calcium channel blocker for at least about 12 hours after oral administration to human patients.
A sustained release oral solid dosage form comprising:
- an effective amount of oxybutynin or a pharmaceutically acceptable salt thereof to provide a therapeutic effect,
- a pH modifying agent;
- a sustained release excipient comprising a gelling agent, said gelling agent comprises a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum, said dosage form providing a therapeutic effect for at least about 24 hours after administration to human patients.
Dependencies are inferred from the claim text.